Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GRDN
GRDN logo

GRDN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Guardian Pharmacy Services Inc (GRDN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
36.380
1 Day change
1.00%
52 Week Range
41.360
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Guardian Pharmacy Services Inc (GRDN) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst ratings, favorable growth trends in the senior housing market, and its position in a defensive sector make it a compelling investment opportunity. While technical indicators are mixed, the long-term growth potential outweighs short-term volatility.

Technical Analysis

The stock's MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 36.858, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 36.991, and resistance is at 40.705. Overall, technical indicators suggest mixed signals but lean towards stability.

Options Data

Bearish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The high Put-Call Ratios indicate bearish sentiment in the options market, but this may not significantly impact long-term investors.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
8

Positive Catalysts

  • Strong Q4 2025 financial performance with 17.44% YoY revenue growth and 75.19% YoY net income growth.

  • Positive analyst ratings with raised price targets (e.g., Truist raised to $43, Jefferies initiated at $44).

  • Favorable growth trends in the senior housing market and Guardian's market share gains.

  • Defensive sector positioning with benefits from AI/automation and strong free cash flow.

Neutral/Negative Catalysts

  • Bearish momentum indicated by MACD and options sentiment.

  • Short-term price trend suggests potential for minor declines (-2.54% in the next month).

Financial Performance

In Q4 2025, Guardian Pharmacy reported a 17.44% YoY revenue increase to $397.6M, a 75.19% YoY net income increase to $20.92M, and a 72.22% YoY EPS increase to $0.31. Gross margin improved by 8.48% to 21.5%. These results highlight strong growth and profitability trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are broadly bullish on Guardian Pharmacy. Truist raised its price target to $43, citing strong demand trends and favorable reimbursement policies. Jefferies initiated coverage with a Buy rating and a $44 price target, emphasizing Guardian's market share gains and accretive acquisitions. Oppenheimer also raised its price target to $38, highlighting sustainable growth drivers and the company's strong position in a growing market.

Wall Street analysts forecast GRDN stock price to fall
2 Analyst Rating
Wall Street analysts forecast GRDN stock price to fall
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 36.020
sliders
Low
34
Averages
34.5
High
35
Current: 36.020
sliders
Low
34
Averages
34.5
High
35
Truist
David MacDonald
Buy
maintain
$38 -> $43
AI Analysis
2026-04-13
Reason
Truist
David MacDonald
Price Target
$38 -> $43
AI Analysis
2026-04-13
maintain
Buy
Reason
Truist analyst David MacDonald raised the firm's price target on Guardian Pharmacy to $43 from $38 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services, or HC. The firm remains broadly bullish on its HC Services coverage universe tied to continued strong demand trends, overarching secular tailwinds and more favorable/stable reimbursement backdrop, with the recent Final Medicare Advantage Rule seen as an "encouraging data point", the analyst tells investors in a research note. Truist adds that it continues to think the sector is well positioned given that it's scaled, domestic and defensive, also noting that the group is a beneficiary of AI/automation/interconnectivity, with strong free cash flow and attractive financial flexibility supporting the ongoing growth investment/M&A/shareholder friendly initiatives.
Jefferies
Buy
initiated
$44
2026-03-30
Reason
Jefferies
Price Target
$44
2026-03-30
initiated
Buy
Reason
Jefferies initiated coverage of Guardian Pharmacy with a Buy rating and $44 price target. The company is positioned post annual 12%-16% EBITDA growth given the secular growth in the senior housing space, the analyst tells investors in a research note. The firm says Guardian's "best-in-class execution" is driving market share gains and operating efficiencies, while its accretive acquisitions also can bring "positive earnings surprises."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GRDN
Unlock Now

People Also Watch